NovaBridge Biosciences
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Srishti Gupta
- Full Time Employees
- 30
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2440 Research Boulevard Rockville MD United States of America 20850
- IPO Date
- Jan 17, 2020
- CIK
- 0001778016
- Website
- novabridge.com
- Similar Companies
- Business
- NovaBridge Biosciences, a global biotechnology platform, has recently undergone a significant corporate transformation, transitioning from its former identity as I-Mab. The company, trading under the new ticker NBP since October 30, 2025, is dedicated to advancing transformative medicines primarily in immuno-oncology and ophthalmic diseases. Its differentiated pipeline includes givastomig, a Claudin 18.2 x 4-1BB bispecific antibody, now preparing for a global randomized Phase 2 clinical study in gastric cancer slated for early 2026. Uliledlimab, a CD73 antibody, is currently in Phase 2 development for various solid tumors. Additionally, ragistomig, an anti-PD-L1 x 4-1BB bispecific antibody, is progressing through Phase 1b clinical trials for solid tumors. A key addition to its portfolio is VIS-101, a novel bifunctional biologic targeting VEGF-A and ANG-2, which is being developed by its newly established subsidiary, Visara, Inc., for ophthalmic indications such as wet age-related macular degeneration and diabetic macular edema, with Phase 3 readiness anticipated in 2026. This strategic shift embraces a "hub-and-spoke" operational model to accelerate asset development and optimize risk management, alongside plans for a dual listing on both NASDAQ and the Hong Kong Stock Exchange to enhance global capital access. NovaBridge Biosciences maintains strategic alliances, including collaborations with ABL Bio for bispecific antibodies and Bristol Myers Squibb for givastomig development. Established in 2014, the company's headquarters are located in Rockville, Maryland.
NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer
NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer
NovaBridge to Present at the 2026 Jefferies Global Healthcare Conference
NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
NovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value
NovaBridge's Givastomig Could Drive A Major Re-Rating
NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update
NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer
NovaBridge Biosciences (NBP) Discusses Phase 2a Clinical Data and Development Plan for VIS-101 in Wet Age-Related Macular Degeneration Transcript
Mid-Cap NovaBridge Biosciences Stock Jumps Fueled By Positive Study Data In Eye Disease
NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study
NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026
NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference
NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform
NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer
NovaBridge Announces Open Market Purchases by Executive Chairman, Fu Wei
What's Going On With NovaBridge Stock Tuesday?
NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer
NovaBridge to Ring the Nasdaq Opening Bell on Friday, January 2, 2026
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO